Trade Summary

2 weeks ago, Orbimed Advisors LLC, serving as Dir, 10% owner at Prelude Therapeutics Inc (PRLD), purchased 2,815,315 shares at $4.44 per share, for a total transaction value of $12,499,999.00. Following this transaction, Orbimed Advisors LLC now holds 1,652,426 shares of PRLD.

This purchase represents a 242.00% decrease in Orbimed Advisors LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, April 21, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 23, 2026, 2 days after the trade was made.

Prelude Therapeutics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.